Gain Therapeutics (GANX) Return on Invested Capital (2020 - 2025)
Gain Therapeutics (GANX) has 6 years of Return on Invested Capital data on record, last reported at 3.82% in Q3 2025.
- For Q3 2025, Return on Invested Capital fell 177.0% year-over-year to 3.82%; the TTM value through Sep 2025 reached 3.82%, down 177.0%, while the annual FY2024 figure was 2.07%, 67.0% down from the prior year.
- Return on Invested Capital reached 3.82% in Q3 2025 per GANX's latest filing, down from 3.7% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.2% in Q2 2021 and bottomed at 3.82% in Q3 2025.
- Average Return on Invested Capital over 5 years is 1.64%, with a median of 1.73% recorded in 2023.
- Peak YoY movement for Return on Invested Capital: crashed -182bps in 2023, then surged 42bps in 2024.
- A 5-year view of Return on Invested Capital shows it stood at 0.38% in 2021, then plummeted by -256bps to 1.36% in 2022, then crashed by -63bps to 2.22% in 2023, then dropped by -14bps to 2.54% in 2024, then plummeted by -51bps to 3.82% in 2025.
- Per Business Quant database, its latest 3 readings for Return on Invested Capital were 3.82% in Q3 2025, 3.7% in Q2 2025, and 3.14% in Q1 2025.